Mimedx Group, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
MiMedx Group, Inc. achieved significant revenue and net income growth in 2025, driven by product expansion, but faces substantial headwinds from new Medicare reimbursement policies effective January 2026.
NASDAQ
10-K: MiMedx Group Reports 8.5% Revenue Growth in 2024, Navigating Reimbursement and Strategic Priorities
MiMedx Group, Inc. announces an 8.5% increase in net sales for 2024, driven by commercial execution and new product demand, while addressing Medicare reimbursement uncertainties and focusing on strategic growth initiatives.
NASDAQ
MiMedx extends its lease agreement for its Marietta, Georgia facility, files its annual report, and refinances its debt to improve its capital structure.